Johnson & Johnson (WBO:JNJ) Total Liabilities : €106,895 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Johnson & Johnson Total Liabilities?

Johnson & Johnson's Total Liabilities for the quarter that ended in Mar. 2025 was €106,895 Mil.

Johnson & Johnson's quarterly Total Liabilities increased from Sep. 2024 (€97,424.23 Mil) to Dec. 2024 (€103,726.37 Mil) and increased from Dec. 2024 (€103,726.37 Mil) to Mar. 2025 (€106,894.85 Mil).

Johnson & Johnson's annual Total Liabilities declined from Dec. 2022 (€104,381.86 Mil) to Dec. 2023 (€90,584.93 Mil) but then increased from Dec. 2023 (€90,584.93 Mil) to Dec. 2024 (€103,726.37 Mil).

Johnson & Johnson Total Liabilities Historical Data

The historical data trend for Johnson & Johnson's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Total Liabilities Chart

Johnson & Johnson Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

91,748.35

95,575.58

104,381.86

90,584.93

103,726.37

Johnson & Johnson Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															93,790.32	101,771.95	97,424.23	103,726.37	106,894.85

Johnson & Johnson Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Johnson & Johnson's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	48056.555	+	(29271.705	+	16759.295
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2337.84	+	6928.525	+	372.45)
	=	103,726

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	171999.32	-	68272.95
	=	103,726

Johnson & Johnson's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	52635.275	+	(35478.375	+	9652.375
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	2245.9	+	6517.55	+	372.45)
	=	106,895

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	179145.675	-	72250.825
	=	106,895

Johnson & Johnson Total Liabilities Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (WBO:JNJ) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico JNJ_KZ:Kazakhstan 1JNJ:Italy JNJd:UK 0R34:UK JNJ0:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Bulgaria JNJ:Argentina

Address

One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.